Cidara Therapeutics Inc
CDTX62.680USD
-0.220-0.35%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
765.27MCap. mercado
PérdidaP/E TTM
Más Datos de Cidara Therapeutics Inc Compañía
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Información de la empresa
Símbolo de cotizaciónCDTX
Nombre de la empresaCidara Therapeutics Inc
Fecha de salida a bolsaApr 15, 2015
Director ejecutivoDr. Jeffrey L. (Jeff) Stein, Ph.D.
Número de empleados38
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 15
Dirección6310 Nancy Ridge Dr Ste 101
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121-3209
Teléfono18587526170
Sitio Webhttps://www.cidara.com/
Símbolo de cotizaciónCDTX
Fecha de salida a bolsaApr 15, 2015
Director ejecutivoDr. Jeffrey L. (Jeff) Stein, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Ritchie
Mr. Brian Ritchie
Investor Relations
Investor Relations
--
--
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
--
--
Mr. Shane Ward
Mr. Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Chief Operating Officer, Chief Legal Officer, Company Secretary
--
--
Dr. Josh Resnick, M.D., J.D.
Dr. Josh Resnick, M.D., J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
29.07%
Hedge Fund
24.64%
Investment Advisor
15.03%
Investment Advisor/Hedge Fund
4.77%
Individual Investor
1.12%
Research Firm
0.52%
Pension Fund
0.12%
Other
24.73%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
130
15.18M
75.27%
+7.25M
2025Q1
124
10.47M
53.54%
+2.71M
2024Q4
122
7.70M
70.35%
+1.07M
2024Q3
109
4.49M
61.04%
+771.77K
2024Q2
109
1.90M
39.70%
+56.88K
2024Q1
108
1.55M
384.06%
-209.94K
2023Q4
111
1.70M
37.69%
-299.58K
2023Q3
119
1.90M
42.77%
-451.34K
2023Q2
126
1.95M
43.98%
-451.51K
2023Q1
153
2.02M
47.21%
-214.92K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
3.37M
16.69%
+2.27M
+207.97%
Jun 26, 2025
Commodore Capital LP
1.18M
5.83%
+1.18M
--
Jun 25, 2025
VR Adviser, LLC
1.05M
5.21%
+285.80K
+37.32%
Mar 31, 2025
TCG Crossover Management, LLC
1.01M
4.99%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
999.41K
4.96%
+885.56K
+777.80%
Apr 09, 2025
Adage Capital Management, L.P.
990.00K
4.91%
+620.05K
+167.60%
Mar 31, 2025
BVF Partners L.P.
924.64K
4.59%
-168.15K
-15.39%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
703.08K
3.49%
--
--
Mar 31, 2025
Canaan Partners
703.08K
3.49%
+703.08K
--
Jul 19, 2024
Vivo Capital, LLC
684.28K
3.39%
+13.68K
+2.04%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Dorsey Wright SmallCap Momentum ETF
0.78%
iShares Micro-Cap ETF
0.15%
Avantis US Small Cap Equity ETF
0.05%
iShares Russell 2000 Value ETF
0.05%
Proshares Ultra Russell 2000
0.03%
ProShares UltraPro Russell2000
0.03%
Global X Russell 2000 ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Ver más
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.78%
iShares Micro-Cap ETF
Proporción0.15%
Avantis US Small Cap Equity ETF
Proporción0.05%
iShares Russell 2000 Value ETF
Proporción0.05%
Proshares Ultra Russell 2000
Proporción0.03%
ProShares UltraPro Russell2000
Proporción0.03%
Global X Russell 2000 ETF
Proporción0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Fecha
Tipo
Relación
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
